LQDA · NASDAQ · Medical - Pharmaceuticals

Liquidia (LQDA)

Commercializes inhaled treprostinil therapies for pulmonary hypertension and develops twice-daily L606.

$68.21
vs last close+1.78 (+2.68%)
  1. Will LQDA's Differentiated PAH Approach Drive Growth?

    Zacks Investment ResearchOther